Close Menu

NEW YORK (GenomeWeb) – Metastatic breast cancer tumors that express the estrogen receptor often acquire HER2 mutations that make them resistant to treatments targeting the estrogen receptor.

About 80 percent of breast cancers are ER+, according to the National Institutes of Health. According to a team led by researchers at the Dana-Farber Cancer Institute, nearly all patients with ER+breast cancers that become metastatic develop resistance to treatments that target the estrogen receptor.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Sponsored by

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.

Sponsored by
Loop Genomics

This webinar will discuss a study that used long-read transcriptome sequencing to explore the distribution of isoforms in colon cancer samples and their metastasis counterparts. 

Sponsored by

This webinar will explain how the Clinic for Special Children in Strasburg, Pennsylvania, has transformed its DNA workflows to improve the diagnosis and treatment of genetic illnesses that are prevalent in the pediatric population of its community.